• Immunubiology Ltd., of Cambridge, UK, said the UK government-backed Biomedical Catalyst awarded the firm about £200,000 (US$300,000) to support preclinical development of pneumococcal vaccine PnuBioVax, which is designed to target a wide range of strains of bacteria.